Literature DB >> 8356890

Psychotic features and the course of Alzheimer's disease: relationship to cognitive, electroencephalographic and computerized tomography findings.

H Förstl1, C Besthorn, C Geiger-Kabisch, H Sattel, U Schreiter-Gasser.   

Abstract

Thirty-one of 50 patients satisfying the NINCDS-ADRDA criteria of probable or possible Alzheimer's disease showed psychotic features during a 2-year observation period. Paranoid delusions were reported in 23 patients, delusional misidentification in 17, visual hallucinations in 16 and auditory hallucinations in 8. All of the 7 patients who died within the observation period had suffered from psychotic features even before the preterminal phase of illness. A faster progression of illness towards more severe stages of dementia was associated with paranoid delusions and hallucinations but not with delusional misidentification. We could not prove a significant influence of age, age of onset, cognitive performance, ventricular enlargement or the severity of quantitative electroencephalographic changes at initial examination on the course of illness. This may indicate that specific psychotic features and their potential organic substrate exert an effect on the progression of illness and on survival in Alzheimer's disease, which is not related to gross brain atrophy and generalized neurophysiological changes.

Entities:  

Mesh:

Year:  1993        PMID: 8356890     DOI: 10.1111/j.1600-0447.1993.tb03394.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  10 in total

Review 1.  Neuropsychiatric aspects of Alzheimer's disease.

Authors:  C Ballard; M Walker
Journal:  Curr Psychiatry Rep       Date:  1999-10       Impact factor: 5.285

Review 2.  Antipsychotic medications and the elderly: effects on cognition and implications for use.

Authors:  M J Byerly; M T Weber; D L Brooks; L R Snow; M A Worley; E Lescouflair
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Factors associated with psychotic symptoms in Alzheimer's disease.

Authors:  N Hirono; E Mori; M Yasuda; Y Ikejiri; T Imamura; T Shimomura; M Ikeda; M Hashimoto; H Yamashita
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

Review 4.  Organic psychosis: Insight into the biology of psychosis.

Authors:  N T Lautenschlager; H Förstl
Journal:  Curr Psychiatry Rep       Date:  2001-08       Impact factor: 5.285

5.  Apolipoprotein E-4 gene dose in clinically diagnosed Alzheimer's disease: prevalence, plasma cholesterol levels and cerebrovascular change.

Authors:  C Czech; H Förstl; F Hentschel; U Mönning; C Besthorn; C Geiger-Kabisch; H Sattel; C Masters; K Beyreuther
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

6.  Similar age-related changes of free intracellular calcium in lymphocytes and central neurons: effects of Alzheimer's disease.

Authors:  H Hartmann; A Eckert; H Förstl; W E Müller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

7.  A comprehensive review of auditory verbal hallucinations: lifetime prevalence, correlates and mechanisms in healthy and clinical individuals.

Authors:  Saskia de Leede-Smith; Emma Barkus
Journal:  Front Hum Neurosci       Date:  2013-07-16       Impact factor: 3.169

Review 8.  Cerebral correlates of psychotic syndromes in neurodegenerative diseases.

Authors:  Kurt A Jellinger
Journal:  J Cell Mol Med       Date:  2012-05       Impact factor: 5.310

9.  Right anterior insula: core region of hallucinations in cognitive neurodegenerative diseases.

Authors:  Frédéric Blanc; Vincent Noblet; Nathalie Philippi; Benjamin Cretin; Jack Foucher; Jean-Paul Armspach; François Rousseau
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

Review 10.  Behavioral and Psychiatric Symptoms of Dementia and Rate of Decline in Alzheimer's Disease.

Authors:  Reena T Gottesman; Yaakov Stern
Journal:  Front Pharmacol       Date:  2019-09-24       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.